Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21369533 | 1.00 | ESR2 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL5341383 | 1.00 | ESR2 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL20015582 | 0.90 | GRM5 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL20015306 | 0.90 | GRM5 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL17296111 | 0.87 | HDAC1 (0.45) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL15626917 | 0.86 | HPGDS (0.42) | ESR2NR1H2GRM5GRM1MAPK1 | |
| SCHEMBL15608127 | 0.86 | HPGDS (0.42) | ESR2NR1H2GRM5GRM1MAPK1 | |
| SCHEMBL15608128 | 0.86 | HPGDS (0.42) | ESR2NR1H2GRM5GRM1MAPK1 | |
| SCHEMBL12266171 | 0.85 | ACHE (0.44) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL2397980 | 0.85 | ACHE (0.44) | ESR2NR1H2GRM5GRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955490-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4186899-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| CN-113508109-B | Substituted heterocyclic amide compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-02-10 | — | — | CN | disclosed |
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11459324-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | BIOGEN MA INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3943488-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-113508109-A | Substituted heterocyclic amide compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-7230022-B2 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005079497-A2 | SUBSTITUTED FUSED BICYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| CN-1440402-A | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1296978-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST3GAL3, ST6GAL1 | ESR2 1870/4885NR1H2 3308/4885GRM5 3219/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ESR2 975/4885NR1H2 149/4885GRM5 1300/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ESR2 975/4885NR1H2 149/4885GRM5 1300/4885 |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | ESR2 1136/4885NR1H2 119/4885GRM5 902/4885 |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | ESR2 4038/4885NR1H2 1388/4885GRM5 2916/4885 |
| US-11459324-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | MGAT3, ST6GAL1, ST3GAL3 | ESR2 1762/4885NR1H2 3275/4885GRM5 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.